Get the Stockscreener App
76.32
0.97%
-0.75
After Hours:
76.32
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC Stock (AZN) Latest News
Astra, J&J and Others Say UK ‘Uninvestable’ Amid Drug Rebate Row - Bloomberg
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
TD Cowen maintains AstraZeneca stock Buy rating, $95 target - Investing.com
AstraZeneca (AZN): Among the Best Diabetes Stocks to Buy According to Billionaires - Yahoo Finance
£10,000 invested in AstraZeneca shares 1 year ago is now worth… - MSN
Breast Cancer Therapeutics Market Size to Reach US$ 63.9 Billion by 2030, Driven by Innovations and Growing Demand, Says The Insight Partners - GlobeNewswire Inc.
Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential - Investing.com UK
AstraZeneca Unit Fights Amgen, Samsung Over Soliris Patent - Law360
AstraZeneca acquires Belgian EsoBiotec for $1 billion - AK&M News
Is AstraZeneca (AZN) the Best European Stock to Buy According to Billionaires? - Insider Monkey
Alteogen in $1.35B Medimmune deal; Astrazeneca bids $1B for Esobiotec - BioWorld Online
AstraZeneca Stock (AZN): Transformative Acquisition in Cancer Care - Value the Markets
AstraZeneca To Buy EsoBiotec in $1B Deal - USA Herald
Sector Update: Health Care Stocks Gain Monday Afternoon -March 17, 2025 at 01:59 pm EDT - Marketscreener.com
Sector Update: Health Care -March 17, 2025 at 01:39 pm EDT - Marketscreener.com
AstraZeneca Buys Into In Vivo Cell Therapy Potential With EsoBiotec - Citeline News & Insights
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal - BioPharma Dive
Eventful Monday For AstraZenecaWhat's Going On? - AOL
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies - TradingView
Covington-Led AstraZeneca To Buy Belgian Biz For Up To $1B - Law360
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals - StockTitan
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca’s Imfinzi gets EU nod for small cell lung cancer By Investing.com - Investing.com South Africa
AstraZeneca to buy cell therapy biotech for up to $1 billion - Fortune
AstraZeneca’s Imfinzi gets EU nod for small cell lung cancer - Investing.com India
AstraZeneca expands with $1bn EsoBiotec acquisition - Investing.com India
AstraZeneca to buy Belgian biotech for close to €1 billion - Luxembourg Times
AstraZeneca to Buy Cell Therapy Biotech for Up to $1 Billion - Bloomberg
AstraZeneca to Buy Cell Therapy Biotech for Up to $1 Billion (3) - Bloomberg Law
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details - Benzinga
Deals of the day-Mergers and acquisitions -March 17, 2025 at 05:46 am EDT - Marketscreener.com
AstraZeneca: exclusive licensing agreement with Alteogen -March 17, 2025 at 05:44 am EDT - Marketscreener.com
AstraZeneca: promising trial in hypoparathyroidism -March 17, 2025 at 05:24 am EDT - Marketscreener.com
AstraZeneca to buy Belgian biotech for up to $1 billion - Al Arabiya English
AstraZeneca: Imfinzi approved by the EU in lung cancer -March 17, 2025 at 05:00 am EDT - Marketscreener.com
AstraZeneca: acquisition of Belgian biotech EsoBiotec -March 17, 2025 at 04:56 am EDT - Marketscreener.com
AstraZeneca to buy EsoBiotec for up to $1 billion - BusinessLine
AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy - Reuters
AstraZeneca to buy Belgian biotech for up to US$1b - The Edge Malaysia
AstraZeneca buys cell therapy biotech in up to $1bn deal - Financial Times
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition (AZN:NASDAQ) - Seeking Alpha
AstraZeneca to acquire EsoBiotec for up to $1 billion By Investing.com - Investing.com UK
AstraZeneca to buy biotechnology company for up to $1bn - Insider Media
AstraZeneca, Alteogen Sign License Deal for Hyaluronidase Enzyme -March 17, 2025 at 03:43 am EDT - Marketscreener.com
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio - Marketscreener.com
AstraZeneca's Hypoparathyroidism Treatment Meets Primary Endpoint in Phase 3 Trial - Marketscreener.com
AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec - DirectorsTalk Interviews
AstraZeneca to buy EsoBiotec for up to $1 billion -March 17, 2025 at 03:20 am EDT - Marketscreener.com
AstraZeneca to Buy Cell Therapy Company EsoBiotec for Up to $1 Billion -March 17, 2025 at 03:21 am EDT - Marketscreener.com
Astrazeneca To Acquire Esobiotec For Up To $1 Billion -March 17, 2025 at 03:19 am EDT - Marketscreener.com
AstraZeneca To Buy Belgium's Cell Therapy Firm EsoBiotec In Up To $1 Bln Deal - Nasdaq
Astrazeneca: Will Acquire Worldwide Rights To Use Alt-B4 To Deve… -March 17, 2025 at 03:16 am EDT - Marketscreener.com
AstraZeneca pays $1bn for biotech that may 'transform cell therapy' - Proactive Investors UK
AstraZeneca to buy EsoBiotec for up to $1 billion -March 17, 2025 at 03:15 am EDT - Marketscreener.com
FTSE 100 Live: Stocks set for positive start in busy central bank week, AstraZeneca splashes the cash - Proactive Investors UK
AstraZeneca, Novo Nordisk, GSK Sign Up for Medicare Drug Price Negotiation in US -March 17, 2025 at 02:37 am EDT - Marketscreener.com
AstraZeneca (LON:AZN) Stock Crosses Above 200 Day Moving Average – What’s Next? - Defense World
AstraZeneca PLC ADR rises Friday, still underperforms market - MarketWatch
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
AstraZeneca director says AI must be a “thought partner” in drug discovery - Yahoo Finance
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer - Quantisnow
NHL Star Power: Erin Andrews Reveals Alarming Cancer Screening Gap in New Campaign - StockTitan
Antiplatelet Drugs Market Is Booming Worldwide 2025-2032 | AstraZeneca Plc, Daiichi Sankyo, Inc., Sanofi - openPR
Del. Justices Told Conflicts Tainted AstraZeneca Co.'s $3B Sale - Law360
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Delaware High Court Weighs Reviving AstraZeneca Shareholder Suit - Bloomberg Law
Capital Group Increases Stake in AstraZeneca - TipRanks
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster - Proactive Investors UK
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):